CA2227065A1 - Liposomes viraux adeno-associes et leur utilisation pour la transfection de cellules dendritiques pour stimuler l'immunite specifique - Google Patents

Liposomes viraux adeno-associes et leur utilisation pour la transfection de cellules dendritiques pour stimuler l'immunite specifique Download PDF

Info

Publication number
CA2227065A1
CA2227065A1 CA002227065A CA2227065A CA2227065A1 CA 2227065 A1 CA2227065 A1 CA 2227065A1 CA 002227065 A CA002227065 A CA 002227065A CA 2227065 A CA2227065 A CA 2227065A CA 2227065 A1 CA2227065 A1 CA 2227065A1
Authority
CA
Canada
Prior art keywords
cells
antigen
tumor
cell
plasmid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002227065A
Other languages
English (en)
Inventor
Ramila Philip
Jane S. Lebkowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2227065A1 publication Critical patent/CA2227065A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)

Abstract

L'invention porte sur une composition servant à la manipulation génétique de cellules comprenant un liposome fait d'une matière lipidique et d'une matière virale adéno-associée (AAV). Cette dernière, normalement un plasmide, comporte une ou plusieurs répétitions terminales du génome du virus AAV. L'invention porte également sur des procédés d'introduction d'ADN dans des cellules à l'aide de complexes AAV/liposome. L'ADN est introduit et exprimé dans des cellules souches, dans des lymphocytes T, dans des cellules tumorales primaires, dans des lignées cellulaires tumorales, dans des cellules dendritiques ou autres cellules présentant des antigènes. De telles cellules transfectées sont utilisées à des fins thérapeutiques pour traiter des sujets atteints du cancer ou d'infections microbiennes. Les cellules dendritiques dont l'ADN code pour des antigènes tumoraux et viraux servent au traitement de sujets atteints de tumeurs ou d'infections virales par administration in vivo ou par activation ex vivo de lymphocytes spécifiques d'antigènes suivie de leur administration au patient.
CA002227065A 1995-07-21 1996-07-19 Liposomes viraux adeno-associes et leur utilisation pour la transfection de cellules dendritiques pour stimuler l'immunite specifique Abandoned CA2227065A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US131295P 1995-07-21 1995-07-21
US60/001,312 1995-07-21
US718495P 1995-11-01 1995-11-01
US60/007,184 1995-11-01
US56628695A 1995-12-01 1995-12-01
US08/566,286 1995-12-01

Publications (1)

Publication Number Publication Date
CA2227065A1 true CA2227065A1 (fr) 1997-02-06

Family

ID=27356895

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002227065A Abandoned CA2227065A1 (fr) 1995-07-21 1996-07-19 Liposomes viraux adeno-associes et leur utilisation pour la transfection de cellules dendritiques pour stimuler l'immunite specifique

Country Status (5)

Country Link
EP (1) EP0840622A4 (fr)
JP (1) JPH11510046A (fr)
AU (1) AU6504596A (fr)
CA (1) CA2227065A1 (fr)
WO (1) WO1997003703A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6734014B1 (en) 1996-02-08 2004-05-11 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating T cells
WO1997029183A2 (fr) * 1996-02-08 1997-08-14 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Procedes et compositions pour transformer des cellules dendritiques et activer des lymphocytes t
EP0906444A1 (fr) * 1996-04-19 1999-04-07 Gabriele Pecher Cellules dendritiques humaines genetiquement transfectees, leur production et leur utilisation, de preference comme vaccins
JP2001515052A (ja) * 1997-08-13 2001-09-18 ザ ユーエイビー リサーチ ファンデーション 遺伝子ベクターの局所施用によるワクチン接種
GB2370573A (en) * 1998-11-18 2002-07-03 Oxford Biomedica Ltd Poxviral vectors
WO2000054839A2 (fr) * 1999-03-15 2000-09-21 Introgen Therapeutics, Inc. Cellules dendritiques transduites avec un gene du soi de type sauvage suscitant des reponses immunitaires antitumorales puissantes
CA2309313A1 (fr) * 1999-08-05 2001-02-05 Board Of Trustees Of The University Of Arkansas Stimulation de la reponse immunitaire par manipulation des cellules dendritiques humaines
WO2001027156A1 (fr) * 1999-10-08 2001-04-19 Curagen Corporation Proteine du type interleukine 2 et acides nucleiques les codant
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
GB0007150D0 (en) * 2000-03-24 2000-05-17 Lamellar Therapeutics Limited Immunotherapeutic methods and compositions
JP5087201B2 (ja) 2000-08-03 2012-12-05 ジョンズ・ホプキンス・ユニバーシティ 抗原に小胞体シャペロンポリペプチドを連結した分子ワクチン
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
EP1644048B1 (fr) 2003-05-05 2015-04-29 Johns Hopkins University Vaccin a adn anti-cancer faisant appel a des plasmides codant une sequence-signal, un antigene oncoproteine mutant, et une proteine de choc thermique
GB0322448D0 (en) 2003-09-25 2003-10-29 Lamellar Therapeutics Ltd Using lamellar bodies to modify linear biological macro molecules
WO2006073970A2 (fr) 2005-01-06 2006-07-13 The Johns Hopkins University Interference arn bloquant l'expression de l'immunite potentialisee de proteines pro-apoptotiques induite par adn et des vaccins de cellules dendritiques transfectes
US8668905B2 (en) 2005-05-12 2014-03-11 University Of South Florida P53 vaccines for the treatment of cancers
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
WO2008153802A1 (fr) * 2007-05-29 2008-12-18 Eusa Pharma, Inc. Traitement ex-vivo du cancer au moyen de psma et d'anticorps de psma
US9789129B2 (en) 2008-04-17 2017-10-17 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
WO2013039989A1 (fr) * 2011-09-12 2013-03-21 Pds Biotechnology Corporation Formulations vaccinales particulaires
WO2013143555A1 (fr) * 2012-03-26 2013-10-03 Biontech Ag Formulation d'arn pour immunothérapie
TWI672149B (zh) 2012-09-21 2019-09-21 美商Ｐｄｓ生技公司 改良之疫苗組成物及使用方法
AU2016354590B2 (en) 2015-11-13 2023-11-23 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
CA3056630A1 (fr) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Immunotolerance ciblee
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
WO2020037303A1 (fr) * 2018-08-16 2020-02-20 The Regents Of The University Of California Boursouflure de membrane cellulaire initiée chimiquement et photochimiquement pour induire la production de vésicules cellulaires, modifications associées, et utilisations associées
KR20220035333A (ko) 2019-05-20 2022-03-22 팬디온 오퍼레이션스, 인코포레이티드 Madcam 표적 면역관용
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126132A (en) * 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
US5252479A (en) * 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5587308A (en) * 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
WO1994021287A1 (fr) * 1993-03-15 1994-09-29 The Government Of The United States Of America As Represented By The Department Of Health And Human Services Cellules dendritiques enrobees de peptide utilisees en tant qu'immunogenes
US5834441A (en) * 1993-09-13 1998-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral (AAV) liposomes and methods related thereto
WO1997029183A2 (fr) * 1996-02-08 1997-08-14 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Procedes et compositions pour transformer des cellules dendritiques et activer des lymphocytes t

Also Published As

Publication number Publication date
EP0840622A1 (fr) 1998-05-13
EP0840622A4 (fr) 2003-01-02
AU6504596A (en) 1997-02-18
JPH11510046A (ja) 1999-09-07
WO1997003703A1 (fr) 1997-02-06

Similar Documents

Publication Publication Date Title
CA2227065A1 (fr) Liposomes viraux adeno-associes et leur utilisation pour la transfection de cellules dendritiques pour stimuler l'immunite specifique
US5834441A (en) Adeno-associated viral (AAV) liposomes and methods related thereto
Cao et al. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity
Irvine et al. Efficient nonviral transfection of dendritic cells and their use for in vivo immunization
EP1012240B1 (fr) Immunotherapie anticancer a base de cellules semi-allogeniques
US5962320A (en) Engineered antigen presenting cells and methods for their use
Prince Gene transfer: a review of methods and applications
JP2002515734A (ja) 遺伝子改変された樹状細胞により媒介される免疫刺激
Herrmann Cancer gene therapy: principles, problems, and perspectives
Tsang et al. The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells
Van Tendeloo et al. Gene-based cancer vaccines: an ex vivo approach
Philip et al. Dendritic cells loaded with MART-1 peptide or infected with adenoviral construct are functionally equivalent in the induction of tumor-specific cytotoxic T lymphocyte responses in patients with melanoma
US20190125848A1 (en) Dendritic cell-extracellular vesicle fusions and methods of using same
EP1214437A1 (fr) Utilisation de vecteurs lentiviraux pour la presentation de l'antigene dans les cellules dendritiques
Philip et al. Gene modification of primary tumor cells for active immunotherapy of human breast and ovarian cancer.
CA2309313A1 (fr) Stimulation de la reponse immunitaire par manipulation des cellules dendritiques humaines
US6652850B1 (en) Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
EP0733373A2 (fr) Compositions et procédés pour augmenter l'immunogénicité des cellules tumorales par l'administration de cellules transformées pour l'expression de B7 et CD2 protéines
AU2004220552A1 (en) IL-2 transmembrane constructs
Lander et al. Development and in vitro characterization of a GM-CSF secreting human ovarian carcinoma tumor vaccine
O’MALLEY JR et al. Department of Otolaryngology-Head & Neck Surgery, Johns Hopkins University, PO Box 41402, Baltimore, MD 21203–6402, USA
Humar Immunotherapy of cancer: protective immunization against tumor cell growth with a mutated p53 allele
Jaffee Methods for Retrovirus-Mediated Gene Transfer to Tumor Cells
Rolland GENE THERAPY FOR CANCER: STRATEGIES AND REVIEW OF CLINICAL TRIALS
Ponsaerts Dendritic cell vaccines for immunity and tolerance: mRNA electroporation as a tool for efficient gene transfer

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead